Overview
Laigo Bio, a Utrecht-based biotech company developing therapies using its Suretac precision membrane protein degradation platform, has secured €11.5 million in seed funding. The round was co-led by Kurma Partners and Curie Capital, aimed at advancing treatments for autoimmune and inflammatory diseases. The company focuses on targeting previously "undruggable" proteins, demonstrating promising preclinical efficacy.
Products
Loading...
Recent Deals
Investors: Kurma Partners, Curie Capital
Laigo Bio, a Utrecht-based biotech company developing therapies using its Suretac precision membrane protein degradation platform, has secured €11.5 million in seed funding. The round was co-led by Kurma Partners and Curie Capital, aimed at advancing treatments for autoimmune and inflammatory diseases. The company focuses on targeting previously "undruggable" proteins, demonstrating promising preclinical efficacy.